BioSpace News Archive

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.

NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that the first patient has been dosed in a Phase II clinical trial with the ClC-1 inhibitor NMD670 in patients impacted by spinal muscular atrophy (SMA).

Spinogenix, Inc. announced that it has been awarded a new grant for nearly $1 million from the U.S. Department of Defense’s Congressionally Directed Medical Research Programs.

Century Therapeutics announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.

In a major achievement, Avalo Therapeutics proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO™ I study evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene.

MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound additional funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients.

Bio-Techne Corporation is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System.